Discharge Diuretic Dose and 30-Day Readmission Rate in Acute Decompensated Heart Failure

Annals of Pharmacotherapy

Volumn 50, Issue 6, 2016, Pages 437-445

  Woodruff, Ashley E ^a,b   Kelley, Ashley M ^c   Hempel, Carolyn A ^a,b   Loeffler, William J ^b,d   Echtenkamp, Christine A ^b,d   Hassan, Amany K ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b Buffalo General Medical Center   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d D'YOUVILLE COLLEGE   (United States)

Author keywords

cardiology; cardiovascular drugs; clinical decision making; clinical research; congestive heart failure; diuretics

Indexed keywords

BUMETANIDE; FUROSEMIDE; TORASEMIDE; LOOP DIURETIC AGENT;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG DOSE INCREASE; FEMALE; HEART EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPERVOLEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ACUTE DISEASE; CLINICAL TRIAL; DOSE RESPONSE; HEART FAILURE; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA;

ACUTE DISEASE; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT READMISSION; RETROSPECTIVE STUDIES; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84967221910     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028016637385     Document Type: Article

References (31)

1. D.Lloyd-JonesR.J.AdamsT.M.Brown. Heart disease and stroke statistics—2010 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation. 2010;121:e1-e170.
2. P.A.HeidenreichN.M.AlbertL.A.Allen. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606-619.
3. Centers for Medicare and Medicaid Services. Performance report on outcome measures, September2013. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/OutcomeMeasures.html. Accessed May 30, 2014.
4. J.B.KostisB.R.DavisJ.Cutler. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212-216.
5. J.A.StaessenJ.G.WangL.ThijsCardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076.
6. A.MaiselY.XueD.J.van Veldhuisen. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol. 2014;114:737-742.
7. J.N.CohnG.Tognoni; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
8. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
9. V.BhatiaN.S.BajajK.Sanam. Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure. Am J Med. 2015;128:715-721.
10. S.D.SolomonD.WangP.Finn. Effect of candesartan on cause-specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2004;110:2180-2183.
11. A.HjalmarsonS.GoldsteinB.Fagerberg. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA. 2000;283:1295-1302.
12. B.PittG.WilliamsW.Remme. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther. 2001;15:79-87.
13. C.W.YancyM.JessupB.Bozkurt. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128:e240-e327.
14. V.HasselbladW.Gattis StoughM.R.Shah. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur Heart J. 2007;9:1064-1069.
15. J.R.WilsonN.ReichekW.B.Dunkman. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 1981;70:234-239, 432.
16. B.P.ChenLoop diuretics: comparison of torsemide, furosemide, and bumetanide. Conn Med. 1996;60:343-345.
17. D.C.BraterClinical pharmacology of loop diuretics. Drugs. 1991;41(suppl 3):14-22.
18. J.S.BloseK.F.AdamsJrJ.H.PattersonTorsemide: a pyridine-sulfonylurea loop diuretic. Ann Pharmacother. 1995;29:396-402.
19. F.ZannadJ.J.McMurrayH.Krum. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2003;348:R1309-R1321.
20. B.PittF.ZannadW.J.Remme. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
21. S.I.ChaudhryY.WangJ.ConcatoT.M.GillH.M.KrumholzPatterns of weight change preceding hospitalization for heart failure. Circulation. 2007;116:1549-1554.
22. J.H.BarsukR.A.GordonE.R.Cohen. A diuretic protocol increases volume removal and reduces readmissions among hospitalized patients with acute decompensated heart failure. Congest Heart Fail. 2013;19:53-60.
23. G.S.FrancisC.BenedictD.E.Johnstone. Comparison of neuroendocrine activation in patients with left-ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left-ventricular dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
24. J.BaylissM.NorellR.CanepaansonG.SuttonP.PoolewilsonUntreated heart-failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17-22.
25. H.A.CooperD.L.DriesC.E.DavisY.L.ShenM.J.DomanskiDiuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-1315.
26. J.M.McCurleyS.U.HanlonS.WeiSkE.F.WedamM.MichalskiM.C.HaigneyFurosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol. 2004;44:1301-1307.
27. A.AhmedA.HusainG.GambassiL.J.Dell’ItaliaR.M.AllmanR.C.BourgeDiuretics increase mortality and hospitalization in ambulatory patients with chronic systolic heart failure: a propensity score analysis. Circulation. 2005;112:II-674.
28. H.M.Abdel-QadirJ.V.TuL.YunP.C.AustinG.E.NewtonD.S.LeeDiuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J. 2010;160:264-271.
29. S.EshaghianT.B.HorwichG.C.FonarowRelation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-1764.
30. M.D.MurrayM.M.DeerJ.A.Ferguson. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513-520.
31. M.G.FelkerK.L.LeeD.A.Bull. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805.